Tag - SLN

Developments

Silence reveals positive topline results from trial of divesiran in PV

Silence Therapeutics (NASDAQ: SLN) has announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV). According...

August 10, 2026

Markets

BTIG starts Silence Therapeutics at buy; PT $32

BTIG initiated coverage of Silence Therapeutics (NASDAQ, AIM: SLN) with a “buy” rating and $32 price target. The stock closed at $16.70 on Nov. 17. The company is a development stage therapeutics company based on nearly...

November 18, 2020

Markets

WB starts Silence Therapeutics at OP; fair value estimate $31

William Blair launched coverage of Silence Therapeutics (NASDAQ:SLN) with an “outperform” rating and fair value estimate of $31. The stock closed at $15.50 on Oct. 26. Silence Therapeutics is developing a GalNAc...

October 27, 2020

Tag - SLN

Silence reveals positive topline results from trial of divesiran in PV

BTIG starts Silence Therapeutics at buy; PT $32

WB starts Silence Therapeutics at OP; fair value estimate $31

Subscribe